Latest News and Press Releases

The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...

NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...

LARBERT, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader...

Team One Appoints Next Generation Leaders; Putting Creativity and Collaboration on A Pedestal with Organizational Moves. LOS ANGELES, Aug. 03, 2023 (GLOBE NEWSWIRE) -- As an agency that began as a...

Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...

LARBERT, United Kingdom, July 06, 2023 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a...

Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...

LARBERT, Scotland and IVER, United Kingdom, April 13, 2023 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach...

Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW...

SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) -- Digital Entertainment Asset (DEA), a Singapore-based global Web3 entertainment company, has launched ‘Product Placement NFTs’ as a new advertising...